ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
July 24, 2024 10:00 ET
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Pancreatic Cancer Market revenue to reach USD 36 Billion by 2036, says Research Nester
November 29, 2023 05:30 ET
|
Research Nester
New York, Nov. 29, 2023 (GLOBE NEWSWIRE) -- The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 36...
ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients
May 30, 2023 10:00 ET
|
ConSynance Therapeutics
RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
January 24, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
November 14, 2022 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
October 05, 2022 09:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 05, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
July 26, 2022 12:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders,...
Human Microbiome Market is expected to foster up to a landmark of USD 1318.72 Million by 2030 with a CAGR value of around 31.08%.
May 24, 2022 10:39 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, United States, May 24, 2022 (GLOBE NEWSWIRE) -- A Human Microbiome comprises archaea, viruses, bacteria, & eukaryotes which reside within & outside our body system. These organisms...